Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy
American Journal of Hematology · 2026-03 · 101 (3) · 570-576
DOI: 10.1002/ajh.70203 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 08.01.2026. Verfasst von Ayalew Tefferi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Peripheral Nervous System Diseases, Pyrimidines, Anemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
- Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ayalew Tefferi, Aref Al-Kali, Talha Badar, Rong He, Naseema Gangat
Zitieren
APA
Tefferi, A., Abdelmagid, M., Palmer, J. M., Al-Kali, A., Yi, C. Y. A., Matin, A., Alkhateeb, H. B., Badar, T., Bashir, Y., Reichard, K. K., He, R., Pardanani, A., & Gangat, N. (2026). Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy. American Journal of Hematology, 101(3), 570-576. https://doi.org/10.1002/ajh.70203
Vancouver
Tefferi A, Abdelmagid M, Palmer JM, Al-Kali A, Yi CYA, Matin A, et al. Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy. American Journal of Hematology. 2026;101(3):570-576. doi:10.1002/ajh.70203
BibTeX
@article{Tefferi2026,
author = {Tefferi, Ayalew and Abdelmagid, Maymona and Palmer, Jeanne M and Al-Kali, Aref and Yi, Cecilia Y Arana and Matin, Aasiya and Alkhateeb, Hassan B and Badar, Talha and Bashir, Yassin and Reichard, Kaaren K and He, Rong and Pardanani, Animesh and Gangat, Naseema},
title = {Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {3},
pages = {570--576},
doi = {10.1002/ajh.70203}
}
EUVIMED